uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Increased mortality after dronedarone therapy for severe heart failure
Show others and affiliations
2008 (English)In: The New England journal of medicine, ISSN 1533-4406, Vol. 358, no 25, 2678-2687 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Dronedarone is a novel antiarrhythmic drug with electrophysiological properties that are similar to those of amiodarone, but it does not contain iodine and thus does not cause iodine-related adverse reactions. Therefore, it may be of value in the treatment of patients with heart failure. METHODS: In a multicenter study with a double-blind design, we planned to randomly assign 1000 patients who were hospitalized with symptomatic heart failure and severe left ventricular systolic dysfunction to receive 400 mg of dronedarone twice a day or placebo. The primary end point was the composite of death from any cause or hospitalization for heart failure. RESULTS: After inclusion of 627 patients (310 in the dronedarone group and 317 in the placebo group), the trial was prematurely terminated for safety reasons, at the recommendation of the data and safety monitoring board, in accordance with the board's predefined rules for termination of the study. During a median follow-up of 2 months, 25 patients in the dronedarone group (8.1%) and 12 patients in the placebo group (3.8%) died (hazard ratio in the dronedarone group, 2.13; 95% confidence interval [CI], 1.07 to 4.25; P=0.03). The excess mortality was predominantly related to worsening of heart failure--10 deaths in the dronedarone group and 2 in the placebo group. The primary end point did not differ significantly between the two groups; there were 53 events in the dronedarone group (17.1%) and 40 events in the placebo group (12.6%) (hazard ratio, 1.38; 95% CI, 0.92 to 2.09; P=0.12). More increases in the creatinine concentration were reported as serious adverse events in the dronedarone group than in the placebo group. CONCLUSIONS: In patients with severe heart failure and left ventricular systolic dysfunction, treatment with dronedarone was associated with increased early mortality related to the worsening of heart failure. (ClinicalTrials.gov number, NCT00543699.)

Place, publisher, year, edition, pages
2008. Vol. 358, no 25, 2678-2687 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-102453DOI: 10.1056/NEJMoa0800456ISI: 000256815100004PubMedID: 18565860OAI: oai:DiVA.org:uu-102453DiVA: diva2:216178

Co-author: Per Blomström, Uppsala universitet, Institutionen för medicinska vetenskaper, Medicin, forskargrupp Arytmi, ingår i Dronedarone Study Group.

Available from: 2009-05-07 Created: 2009-05-07 Last updated: 2016-10-03Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Blomstrom, Per
By organisation
Internal Medicine
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 268 hits
ReferencesLink to record
Permanent link

Direct link